Research at the Centre Léon Bérard

Introduction

Clinical research in Oncology is an essential stage since it measures tolerance and efficiency of drugs directly on patients. Patients receive these new treatments or treatment protocols in clinical trials.
Clinical and innovation Research at the CLB is led by Dr David Pérol. He aims to carry on evaluation of new therapies in the coming years, especially through clinical trials focused on the identification of molecular alterations to try and adapt treatments according to genetic abnormalities detected in tumours, what is usually called: precision medicine.

Continued innovation in all areas for the benefit of local patients as well as those from abroad

19% of patients managed at the Centre Léon Bérard were included in clinical trials.

daycarehospital
  • Vidéo essai clinique
    Hôpital

    Clinical trials

    Follow the pathway of a patient included in a clinical trials at the Centre Léon Bérard

  • Clinical trials: key figures
    • 2071

      patients included in a clinical trials

    • 224

      clinical trials open to patients

More than 220 clinical trials are open each year at the CLB

In 2017, 19% of patients managed at the Centre Léon Bérard were included in clinical trials and this moves our Centre to the fore of comprehensive Cancer centres talking in terms of recruitment. 

More than 200 clinical trials are open each year at the CLB.

chefs de projet en recherche clinique

 

Clinical and innovation Research at the CLB

Clinical and innovation research is composed of 4 expertise centres and 2 supportive platforms:

Expertise centres:

  • Promoting centre
  • Investigation centre
  •  Biostats centre
  • Innovation and strategy centre

Supportive platforms:

  • Data management
  • Quality and regulatory platform

Did you know ?

ISO 9001 : quality guaranty

Clinical research has been certified ISO 9001 since 2013. This international registered standard guaranties to all, patients, physicians, academic and industrial partners, a high level of quality and safety in the organization of clinical trials.

The CLB became thus, one of the few hospitals in France, the only one in the Rhône-Alpes region, to get this certification.

The Centre Léon Bérard: a long experience in clinical Research

With over 30 years of experience, the clinical research of the Centre Léon Bérard lays on a strong interaction between medical teams and basic and transfer research teams. These collaborations promoted innovating transfer technologies towards clinical applications to make patients benefit from pioneer therapeutics in the management of cancers.

Acknowledgment of Excellence and expertise of the Centre Léon Bérard

Clinical research is structured and professionalized. More than 60 positions are dedicated to this activity on site. The Centre Léon Bérard was thus certified by the National Cancer Institute (INCa) as an oncology early clinical trial centre (CLIP2) and Data Proceeding Centre (CTD) on oncology clinical trials. The Centre Léon Bérard has been certified as well by the French Minister for Health as an Oncology Clinical Research Centre (CRC) within the Health Coordination Group (GCS) Lyon University Oncology.

Early trials (phase I and II) are coordinated within the early phase unit headed by Dr Philippe Cassier.

Likewise, technical or medical and technical platforms (pharmacy of the CLB, Biological Resource Centre) and transfer research platforms of the Cancer Research Centre of Lyon provide their expertise and support, essential to conduct clinical research projects.

The CREC (clinical Trial Review Committee) headed by Dr Thomas Bachelot, reviews all clinical research protocols before giving the authorization to conduct trials in the Centre Léon Bérard.

These structures are closely linked to experienced medical units in the management of patients recruited in clinical trials

The centre Léon Bérard is a charter member of the PARCC (platform of support for oncology clinical research), multi-institutional structure which aims to support oncology clinical research in the Auvergne Rhône-Alpes region. Supported by the French Ligue against cancer and the Canceropôle Lyon Auvergne Rhône-Alpes, the PARCC provides a methodological, logistical and financial support to promoters from partner institutions.

Clinical and innovation research Director

Dr David Pérol

david.perol@lyon.unicancer.fr

Tél.: +33 (0)4 78 78 27 52

un membre de la recherche clinique

 

Focus on

PAZOGIST study on Gastro Intestinal Stromal Tumours

PAZOGIST is a phase II randomized study from the Centre Léon Bérard (Jean-Yves Blay, Isabelle Laure Ray-Coquard, David Pérol, Philippe Cassier...) which outcomes are available on the following link: Pazogist study

Chemoimmune: immunotherapy in breast cancer

CHEMOIMMUNE is a phase II study coordinated by CLB medical oncologist Dr. Olivier Tredan. It aims to evaluate the effectiveness of immunotherapy in patients with breast cancer. Thirty-six patients will be included in this open study in five other French centers of investigation.

ISI-JX: a new strategy of immunotherapy in situ

The early phase trial, ISI-JX, is a phase I ascending dose clinical trial, evaluating a new strategy of immunotherapy in situ. It will make it possible to determine the recommended dose, evaluate the anti-tumor activity induced and confirm the tolerance of the treatments administered. It results from the work carried out at the CLB site, within the Cancer Research Center of Lyon (CRCL).